Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GRI Bio ( (GRI) ) has shared an update.
GRI Bio, Inc. amended its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC on January 29, 2026, effective January 28, 2026, significantly increasing the potential size of the offering. The company raised the aggregate cap on common stock issuable under the program from $10 million to up to $60 million, subject to the amount registered on its prospectus supplement, and obtained waivers of certain provisions in a December 11, 2025 securities purchase agreement to permit these issuances, expanding its flexibility to raise capital through ongoing share sales.
The most recent analyst rating on (GRI) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
The score is held down primarily by persistent operating losses and significant cash burn alongside a technically weak downtrend. Low leverage and multiple positive Phase 2a IPF data releases provide some support, but listing/compliance actions (reverse split and Nasdaq notices) and loss-making fundamentals keep the overall assessment cautious.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
Average Trading Volume: 314,125
Technical Sentiment Signal: Sell
Current Market Cap: $2.2M
See more insights into GRI stock on TipRanks’ Stock Analysis page.